Gene therapy instilled into kidney shows promise for rare cancer
NCT ID NCT06668493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a gene therapy called nadofaragene firadenovec for people with low-grade upper tract urothelial cancer. The drug is instilled directly into the kidney's renal pelvis. The study aims to see if it is safe and can eliminate the cancer. Twenty adults with confirmed low-grade tumors will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nadofaragene firadenovec (a gene therapy drug instilled into the kidney)
What this could lead to
If successful, this could offer a new treatment option for low-grade upper tract urothelial cancer, potentially avoiding the need for kidney removal.
What could go wrong
This is an early phase 1/2 trial with only 20 participants, so results may not apply to everyone. Side effects and lack of response are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine (Houston)
RECRUITINGHouston, Texas, 77030, United States
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center - Genitourinary (GU) Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Mayo Clinic
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic - Rochester Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
-
Mayo Clinic - Scottsdale Arizona
RECRUITINGScottsdale, Arizona, 85054, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Providence Saint John's Cancer Institute
RECRUITINGSanta Monica, California, 90404, United States
-
University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States